Vertaling van "other drugs " (Frans → Nederlands) :

Such risks and uncertainties include, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development; whether and when a new drug application for tafamidis will be filed with the FDA; decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for tafamidis and that may be filed for any other product candidates that may be generated by FoldRx’s technology platform as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of tafamidis and such other product candidates; and competitive developments.
This release contains forward-looking information about an agreement by Pfizer to acquire FoldRx, and about FoldRx’s product candidate tafamidis, its other clinical and preclinical development programs and its technology platform, including their potential benefits, that involves substantial risks and uncertainties. Such risks and uncertainties include, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development; whether and when a new drug application for tafamidis will be filed with the FDA; decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for tafamidis and that may be filed for any other product candidates that may be generated by FoldRx’s technology platform as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of tafamidis and such other product candidates; and competitive developments. A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2009 and in its reports on Form 10-Q and Form 8-K.

INHALANTS M01A ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, -0,7 5,4 48.607.976 2,8 NON-STEROIDS C09D ANGIOTENSIN II ANTAGONISTS, COMBINATIONS 16,7 29,3 48.458.787 23,2 C08C SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY 4,8 10,5 47.845.796 8,1 VASCULAR EFFECTS L02B HORMONE ANTAGONISTS AND RELATED AGENTS 18,1 16,3 40.001.905 12,5 C01D VASODILATORS USED IN CARDIAC DISEASES -5,3 -0,3 37.257.508 -1,4 B02B VITAMIN K AND OTHER HEMOSTATICS x x 35.730.154 x N06D ANTI-DEMENTIA DRUGS 12,9 12,5 30.096.154 10,2 L02A HORMONES AND RELATED AGENTS -2,3 1,4 29.043.416 -0,3 N04B DOPAMINERGIC AGENTS 11,0 11,6 27.632.755 9,9 L01X OTHER ANTINEOPLASTIC AGENTS 11,6 23,7 26.993.829 15,7
M01A ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, -0,7 5,4 48.607.976 2,8 NON-STEROIDS C09D ANGIOTENSIN II ANTAGONISTS, COMBINATIONS 16,7 29,3 48.458.787 23,2 C08C SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY 4,8 10,5 47.845.796 8,1 VASCULAR EFFECTS L02B HORMONE ANTAGONISTS AND RELATED AGENTS 18,1 16,3 40.001.905 12,5 C01D VASODILATORS USED IN CARDIAC DISEASES -5,3 -0,3 37.257.508 -1,4 B02B VITAMIN K AND OTHER HEMOSTATICS x x 35.730.154 x N06D ANTI-DEMENTIA DRUGS 12,9 12,5 30.096.154 10,2 L02A HORMONES AND RELATED AGENTS -2,3 1,4 29.043.416 -0,3 N04B DOPAMINERGIC AGENTS 11,0 11,6 27.632.755 9,9 L01X OTHER ANTINEOPLASTIC AGENTS 11,6 23,7 26.993.829 15,7

A10B BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS 4,4 13,3 50.835.282 12,5 R03B OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, 8,5 6,6 49.172.433 5,7
A10B BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS 4,4 13,3 50.835.282 12,5 R03B OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS 8,5 6,6 49.172.433 5,7

la création d’une banque de données qui reprend l’ensemble des spécialités pharmaceutiques remboursables ainsi que les critères administratifs et pharmacothérapeutiques de remboursement ( [http ...]
de oprichting van een gegevensbank die alle vergoedbare farmaceutische specialiteiten alsook de administratieve en de farmacotherapeutische vergoedingscriteria bevat ( [http ...]

26Octobre1999 ( [http ...]
hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic.

Rapport du jury de la réunion de consensus du 26 Octobre1999 ( [http ...]
RIZIV. Juryrapport van de consensusconferentie van 26 oktober 1999 ( [http ...]

- il s'agit d'un médicament de la liste suivante de codes ATC: R01 Nasal preparations, R03 Drugs for obstructive airway diseases, R05 Cough and cold preparations; R06 Antihistamines for systemic use, R07 Other respiratory system products, S01G Decongestants and antiallergics.
- het betreft een geneesmiddel uit volgende lijst ATC codes: R01 Nasal preparations, R03 Drugs for obstructive airway diseases, R05 Cough and cold preparations; R06 Antihistamines for systemic use, R07 Other respiratory system products, S01G Decongestants and antiallergics.

Un certain nombre de nouvelles règles concernant le remboursement des hypolipidémiants sont entrées en vigueur en Belgique le 1 décembre 2003 (voir site web de l’INAMI: [http ...]
Sinds 1 december 2003 zijn er in België een aantal nieuwe regels in verband met terugbetaling van de hypolipemiërende middelen (zie website van het RIZIV: [http ...]

C07AB07 - Bisoprolol Yes 231 224 0 97,0% C10AA04 - Fluvastatin No 196 0 0 0,0% C02AC05 - Moxonidine Yes 187 187 0 100,0% N02AB03 - Fentanyl Yes 180 180 0 100,0% N04BD02 - Rasagiline No 168 0 0 0,0% N04BC05 - Pramipexole No 168 0 0 0,0% G03AA10 - Gestodene and estrogen Yes 168 0 0 0,0% A02BC01 - Omeprazole Yes 168 168 0 100,0% R03AK03 - Fenoterol and other drugs for obstructive airway diseases No 167 0 0 0,0%
A02BC01 - Omeprazole Yes 658 658 0 100,0% C08CA01 - Amlodipine Yes 568 568 0 100,0% N06AB04 - Citalopram Yes 560 560 0 100,0% R05CB01 - Acetylcysteine Yes 540 360 0 66,7% R06AE07 - Cetirizine Yes 460 180 0 39,1% C07AB07 - Bisoprolol Yes 448 448 0 100,0% J01CA04 - Amoxicillin Yes 443 443 0 100,0% M01AE02 - Naproxen Yes 429 0 0 0,0% C09DA04 - Irbesartan and diuretics No 420 0 0 0,0%

la mise à disposition de la base de données des spécialités pharmaceutiques remboursables ( [http ...]
specialiteiten ( [http ...]